ACR–SPR–SSR PRACTICE PARAMETER FOR THE PERFORMANCE AND INTERPRETATION OF MAGNETIC RESONANCE IMAGING (MRI) OF BONE AND SOFT-TISSUE TUMORS

1. [3275960] Pathria MN, Zlatkin M, Sartoris DJ, Scheible W, Resnick D. Ultrasonography of the popliteal fossa and lower extremities. Radiol Clin North Am. 1988 Jan;26(1):77-85.
2. [1950879] Taylor GA, Perlman EJ, Scherer LR, Gearhart JP, Leventhal BG, Wiley J. Vascularity of tumors in children: evaluation with color Doppler imaging. AJR Am J Roentgenol. 1991 Dec;157(6):1267-71.
3. [24848826] Carra BJ, Bui-Mansfield LT, O'Brien SD, Chen DC. Sonography of musculoskeletal soft-tissue masses: techniques, pearls, and pitfalls. [Review]. AJR Am J Roentgenol. 202(6):1281-90, 2014 Jun.
4. [6099221] Lois JF, Fischer HJ, Deutsch LS, Stambuk EC, Gomes AS. Angiography in soft tissue sarcomas. Cardiovasc Intervent Radiol. 1984;7(6):309-16.
5. [12192559] Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54.
6. [12732672] Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003 May;44(5):717-24.
7. [19048352] Lisle JW, Eary JF, O'Sullivan J, Conrad EU. Risk assessment based on FDG-PET imaging in patients with synovial sarcoma. Clin Orthop Relat Res. 2009 Jun;467(6):1605-11.
8. [9619933] Lucas JD, O'Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998 May;80(3):441-7.
9. [18024454] Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology. 245(3):839-47, 2007 Dec.
10. [18048826] Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 25(34):5435-41, 2007 Dec 01.
11. [18322413] Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie. 2008 Mar;31(3):107-12.
12. [15578712] Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 103(2):339-48, 2005 Jan 15.
13. [12605277] Vernon CB, Eary JF, Rubin BP, Conrad EU, Schuetze S. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol. 2003 Mar;32(3):139-42.
14. [18670853] Ye Z, Zhu J, Tian M, et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET. Ann Nucl Med. 22(6):475-80, 2008 Jul.
15. [14508272] Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28(10):815-820.
16. [16715239] Strobel K, Bode B, Lardinois D, Exner U. PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skeletal Radiol. 2007 Jun;36 Suppl 1():S24-8.
17. [11685477] Oliveira AM, Nascimento AG. Grading in soft tissue tumors: principles and problems. Skeletal Radiol. 2001 Oct;30(10):543-59.
18. [16554565] Stacy GS, Mahal RS, Peabody TD. Staging of bone tumors: a review with illustrative examples. AJR Am J Roentgenol. 2006 Apr;186(4):967-76.
19. [11505926] Aboulafia AJ, Kennon RE, Jelinek JS. Begnign bone tumors of childhood. J Am Acad Orthop Surg. 1999;7(6):377-88.
20. [2408105] Dalinka MK, Zlatkin MB, Chao P, Kricun ME, Kressel HY. The use of magnetic resonance imaging in the evaluation of bone and soft-tissue tumors. Radiol Clin North Am. 1990 Mar;28(2):461-70.
22. [12409691] Hoffer FA. Primary skeletal neoplasms: osteosarcoma and ewing sarcoma. Top Magn Reson Imaging. 2002 Aug;13(4):231-9.
23. [12091667] Kransdorf MJ, Bancroft LW, Peterson JJ, Murphey MD, Foster WC, Temple HT. Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma. Radiology. 2002 Jul;224(1):99-104.
24. [2763953] Kransdorf MJ, Jelinek JS, Moser RP, et al. Soft-tissue masses: diagnosis using MR imaging. AJR Am J Roentgenol. 1989 Sep;153(3):541-7.
25. [10088064] Ma LD. Magnetic resonance imaging of musculoskeletal tumors: skeletal and soft tissue masses. Curr Probl Diagn Radiol. 1999;28(2):29-62.
26. [8217201] Murphey MD, Gross TM, Rosenthal HG, Neff JR. Magnetic resonance imaging of soft tissue and cystic masses about the knee. Top Magn Reson Imaging. 1993;5(4):263-82.
27. [12462464] Nomikos GC, Murphey MD, Kransdorf MJ, Bancroft LW, Peterson JJ. Primary bone tumors of the lower extremities. Radiol Clin North Am. 2002 Sep;40(5):971-90.
28. [3588912] Pettersson H, Gillespy T, Hamlin DJ, et al. Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities. Radiology. 1987 Jul;164(1):237-41.
29. [15066597] Ritchie DA, Davies AM. MR imaging of tumors and tumor-like lesions of the shoulder girdle. Magn Reson Imaging Clin N Am. 2004 Feb;12(1):125-41, vii.
30. [10542044] Sundaram M. Magnetic resonance imaging for solitary lesions of bone: when, why, how useful?. J Orthop Sci. 1999;4(5):384-96.
31. [3238437] Sundaram M, McGuire MH. Computed tomography or magnetic resonance for evaluating the solitary tumor or tumor-like lesion of bone?. Skeletal Radiol. 1988;17(6):393-401.
32. [3398729] Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging. 1988;6(3):237-248.
33. [2119115] Sundaram M, McLeod RA. MR imaging of tumor and tumorlike lesions of bone and soft tissue. AJR. 1990; 155(4):817-824.
34. [2723178] Tehranzadeh J, Mnaymneh W, Ghavam C, Morillo G, Murphy BJ. Comparison of CT and MR imaging in musculoskeletal neoplasms. J Comput Assist Tomogr. 1989;13(3):466-72.
35. [3055041] Bloem JL, Taminiau AH, Eulderink F, Hermans J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology. 1988; 169(3):805-810.
36. [3257620] Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, Brennan MF. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol. 1988 Mar;150(3):615-20.
37. [2120933] Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR. 1990; 155(5):1043-1048.
38. [8988217] Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202(1):237-246.
39. [11904686] Saifuddin A. The accuracy of imaging in the local staging of appendicular osteosarcoma. Skeletal Radiol. 2002 Apr;31(4):191-201.
40. [14519874] Elias DA, White LM, Simpson DJ, et al. Osseous invasion by soft-tissue sarcoma: assessment with MR imaging. Radiology. 2003 Oct;229(1):145-52.
41. [7449206] Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106-20.
42. [16436820] Feydy A, Anract P, Tomeno B, Chevrot A, Drape JL. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. Radiology. 238(2):611-21, 2006 Feb.
43. [10350347] Moulopoulos LA, Dimopoulos MA, Vourtsi A, Gouliamos A, Vlahos L. Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. Leuk Lymphoma. 1999 Jun;34(1-2):179-84.
44. [7529935] Swan JS, Grist TM, Sproat IA, Heiner JP, Wiersma SR, Heisey DM. Musculoskeletal neoplasms: preoperative evaluation with MR angiography. Radiology. 1995; 194(2):519-524.
45. [12850925] Baur A, Stäbler A, Wendtner CM, et al. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia. 2003;19(4):391-401.
46. [10101637] Bearcroft PW, Davies AM. Follow-up of musculoskeletal tumours. 2. Metastatic disease. Eur Radiol. 1999;9(2):192-200.
47. [1584945] Biondetti PR, Ehman RL. Soft-tissue sarcomas: use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging. Radiology. 1992 Jun;183(3):845-8.
48. [1853821] Choi H, Varma DG, Fornage BD, Kim EE, Johnston DA. Soft-tissue sarcoma: MR imaging vs sonography for detection of local recurrence after surgery. AJR Am J Roentgenol. 1991 Aug;157(2):353-8.
49. [12832588] Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003 Jul;228(1):271-8.
50. [1892044] Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol. 1991 Oct;157(4):825-33.
51. [2321049] Reuther G, Mutschler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol. 1990;19(2):85-90.
52. [9526770] van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol. 1998 Feb;27(2):57-71.
53. [3588913] Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology. 1987 Jul;164(1):243-5.
54. [8259417] Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology. 1994; 190(1):263-268.
55. [8564690] Varma DG, Jackson EF, Pollock RE, Benjamin RS. Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Magn Reson Imaging Clin N Am. 1995 Nov;3(4):695-712.
56. [10616815] Verstraete KL, Lang P. Post-therapeutic magnetic resonance imaging of bone tumors. Top Magn Reson Imaging. 1999 Aug;10(4):237-46.
57. [10663582] Bush CH. The magnetic resonance imaging of musculoskeletal hemorrhage. Skeletal Radiol. 2000 Jan;29(1):1-9.
58. [1732962] Fritz RC, Helms CA, Steinbach LS, Genant HK. Suprascapular nerve entrapment: evaluation with MR imaging. Radiology. 1992 Feb;182(2):437-44.
59. [11549164] Kothari NA, Pelchovitz DJ, Meyer JS. Imaging of musculoskeletal infections. Radiol Clin North Am. 2001 Jul;39(4):653-71.
60. [8273696] Lenchik L, Dovgan DJ, Kier R. CT of the iliopsoas compartment: value in differentiating tumor, abscess, and hematoma. AJR. 1994;162(1):83-86.
61. [1656483] Panicek DM, Casper ES, Brennan MF, Hajdu SI, Heelan RT. Hemorrhage simulating tumor growth in malignant fibrous histiocytoma at MR imaging. Radiology. 1991 Nov;181(2):398-400.
62. [10464796] Roebuck DJ. Skeletal complications in pediatric oncology patients. Radiographics. 1999;19(4):873-85.
63. [7976893] Rubin DA, Kneeland JB. MR imaging of the musculoskeletal system: technical considerations for enhancing image quality and diagnostic yield. AJR Am J Roentgenol. 1994 Nov;163(5):1155-63.
64. [11316360] Struk DW, Munk PL, Lee MJ, Ho SG, Worsley DF. Imaging of soft tissue infections. Radiol Clin North Am. 2001 Mar;39(2):277-303.
65. [2934963] Unger EC, Glazer HS, Lee JK, Ling D. MRI of extracranial hematomas: preliminary observations. AJR Am J Roentgenol. 1986 Feb;146(2):403-7.
66. [-3098654] American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Available at: https://gravitas.acr.org/PPTS/GetDocumentView?docId=146+&releaseId=2
67. [-3197748] American College of Radiology. ACR–SPR Practice Parameter for the use of Intravascular Contrast Media. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=142+&releaseId=2
68. [-3188535] American College of Radiology. ACR Committee on Drugs and Contrast Media. Manual on Contrast Media.  Available at: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Contrast-Manual.
70. [21678113] Edwards AD, Arthurs OJ. Paediatric MRI under sedation: is it necessary? What is the evidence for the alternatives?. Pediatr Radiol. 2011 Nov;41(11):1353-64.
71. [3945757] Kneeland JB, Shimakawa A, Wehrli FW. Effect of intersection spacing on MR image contrast and study time. Radiology. 1986 Mar;158(3):819-22.
72. [3363140] Pettersson H, Slone RM, Spanier S, Gillespy T, Fitzsimmons JR, Scott KN. Musculoskeletal tumors: T1 and T2 relaxation times. Radiology. 1988 Jun;167(3):783-5.
73. [18046547] Jaramillo D, Laor T. Pediatric musculoskeletal MRI: basic principles to optimize success. Pediatr Radiol. 2008 Apr;38(4):379-91.
74. [12964073] Romaneehsen B, Oberholzer K, Müller LP, Kreitner KF. Rapid musculoskeletal magnetic resonance imaging using integrated parallel acquisition techniques (IPAT)--initial experiences. Rofo. 2003 Sep;175(9):1193-7.
75. [-3197619] American College of Radiology. ACR–SIR Practice Parameter For Minimal and/or Moderate Sedation/Analgesia. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=95+&releaseId=2
76. [9393511] Erickson SJ. High-resolution imaging of the musculoskeletal system. Radiology. 1997 Dec;205(3):593-618.
77. [10194785] Delfaut EM, Beltran J, Johnson G, Rousseau J, Marchandise X, Cotten A. Fat suppression in MR imaging: techniques and pitfalls. Radiographics. 1999;19(2):373-82.
78. [8249717] Mirowitz SA. Fast scanning and fat-suppression MR imaging of musculoskeletal disorders. AJR Am J Roentgenol. 1993;161(6):1147-1157.
79. [11641161] Rybicki FJ, Chung T, Reid J, Jaramillo D, Mulkern RV, Ma J. Fast three-point dixon MR imaging using low-resolution images for phase correction: a comparison with chemical shift selective fat suppression for pediatric musculoskeletal imaging. AJR Am J Roentgenol. 2001 Nov;177(5):1019-23.
80. [2784268] Shuman WP, Baron RL, Peters MJ, Tazioli PK. Comparison of STIR and spin-echo MR imaging at 1.5 T in 90 lesions of the chest, liver, and pelvis. AJR Am J Roentgenol. 1989 Apr;152(4):853-9.
81. [7588872] Ziedses des Plantes BG, Koster K. Comparison of low-field versus high-field MR imaging. Eur J Radiol. 1995 Jul;20(2):156-8.
82. [-3197845] Kransdorf MJ, Murphey, MD. Imaging of Soft Tissue Tumors. 2nd ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2006.
83. [3187003] Rosen BR, Fleming DM, Kushner DC, et al. Hematologic bone marrow disorders: quantitative chemical shift MR imaging. Radiology. 1988 Dec;169(3):799-804.
84. [16244268] Zajick DC, Jr., Morrison WB, Schweitzer ME, Parellada JA, Carrino JA. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology. 2005;237(2):590-596.
85. [11891975] van Rijswijk CS, Kunz P, Hogendoorn PC, Taminiau AH, Doornbos J, Bloem JL. Diffusion-weighted MRI in the characterization of soft-tissue tumors. J Magn Reson Imaging. 2002; 15(3):302-307.
86. [21182138] Oka K, Yakushiji T, Sato H, et al. Usefulness of diffusion-weighted imaging for differentiating between desmoid tumors and malignant soft tissue tumors. J Magn Reson Imaging. 33(1):189-93, 2011 Jan.
87. [23151862] Neubauer H, Evangelista L, Hassold N, et al. Diffusion-weighted MRI for detection and differentiation of musculoskeletal tumorous and tumor-like lesions in pediatric patients. World J Pediatr. 8(4):342-9, 2012 Nov.
88. [25805331] Ahlawat S, Khandheria P, Subhawong TK, Fayad LM. Differentiation of benign and malignant skeletal lesions with quantitative diffusion weighted MRI at 3T. Eur J Radiol. 2015 Jun;84(6):S0720-048X(15)00111-4.
89. [12794613] Gielen JL, De Schepper AM, Parizel PM, Wang XL, Vanhoenacker F. Additional value of magnetic resonance with spin echo T1-weighted imaging with fat suppression in characterization of soft tissue tumors. J Comput Assist Tomogr. 2003;27(3):434-41.
91. [3287441] Haggar AM, Froelich JW. MR imaging strategies in primary and metastatic malignancy. Radiol Clin North Am. 1988 May;26(3):689-96.
93. [3495155] Haacke EM, Lenz GW. Improving MR image quality in the presence of motion by using rephasing gradients. AJR Am J Roentgenol. 1987 Jun;148(6):1251-8.
94. [25461304] Lavdas E, Mavroidis P, Kostopoulos S, et al. Reduction of motion, truncation and flow artifacts using BLADE sequences in cervical spine MR imaging. Magn Reson Imaging. 2015 Feb;33(2):S0730-725X(14)00339-7.
95. [8061453] Benedikt RA, Jelinek JS, Kransdorf MJ, Moser RP, Berrey BH. MR imaging of soft-tissue masses: role of gadopentetate dimeglumine. J Magn Reson Imaging. 1994;4(3):485-90.
96. [2717749] Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA--enhanced MR imaging. Radiology. 1989;171(3):767-773.
97. [9285993] Kransdorf MJ, Murphey MD. The use of gadolinium in the MR evaluation of soft tissue tumors. Semin Ultrasound CT MR 1997;18:251-68.
98. [1729290] Mirowitz SA, Totty WG, Lee JK. Characterization of musculoskeletal masses using dynamic Gd-DTPA enhanced spin-echo MRI. J Comput Assist Tomogr. 1992;16(1):120-5.
99. [2845586] Pettersson H, Eliasson J, Egund N, et al. Gadolinium-DTPA enhancement of soft tissue tumors in magnetic resonance imaging--preliminary clinical experience in five patients. Skeletal Radiol. 1988;17(5):319-23.
100. [11387129] Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Dynamic Contrast-Enhanced MR Imaging for Soft Tissue Sarcomas. Semin Musculoskelet Radiol. 1999;3(2):101-114.
101. [10927164] Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol. 2000 Jun;34(3):229-46.
102. [2195271] Hanna SL, Langston JW, Gronemeyer SA, Fletcher BD. Subtraction technique for contrast-enhanced MR images of musculoskeletal tumors. Magn Reson Imaging. 1990;8(3):213-5.
103. [15741025] Tuncbilek N, Karakas HM, Okten OO. Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol. 53(3):500-5, 2005 Mar.
104. [9722866] van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology. 1998; 208(3):821-828.
105. [15459325] van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology. 2004; 233(2):493-502.
106. [1319075] Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992 Jul;184(1):243-8.
107. [11953613] Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clin Orthop Relat Res. 2002 Apr;(397):212-27.
108. [7934655] Verstraete KL, Dierick A, De Deene Y, et al. First-pass images of musculoskeletal lesions: a new and useful diagnostic application of dynamic contrast-enhanced MRI. Magn Reson Imaging. 1994;12(5):687-702.
109. [12773675] Liu PT, Chivers FS, Roberts CC, Schultz CJ, Beauchamp CP. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging. Radiology. 2003;227(3):691-700.
110. [36436964] Stanborough R, Demertzis JL, Wessell DE, et al. ACR Appropriateness Criteria® Malignant or Aggressive Primary Musculoskeletal Tumor-Staging and Surveillance: 2022 Update. J Am Coll Radiol 2022;19:S374-S89.
111. [8544659] Ballinger JR, Kang H, Sweeney CA, Scott JD, Croker BP, Scott KN. P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice. Magn Reson Imaging. 1995;13(6):877-83.
112. [11920514] Kettelhack C, Wickede Mv, Vogl T, Schneider U, Hohenberger P. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer. 2002 Mar 01;94(5):1557-64.
113. [10080272] Millis K, Weybright P, Campbell N, et al. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999 Feb;41(2):257-67.
114. [9176889] Möller HE, Vermathen P, Rummeny E, et al. In vivo 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy. NMR Biomed. 1996 Dec;9(8):347-58.
115. [9367021] Singer S, Millis K, Souza K, Fletcher C. Correlation of lipid content and composition with liposarcoma histology and grade. Ann Surg Oncol. 1997;4(7):557-63.
116. [14695223] Zakian KL, Shukla-Dave A, Meyers P, et al. Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 2003 Dec 15;63(24):9042-7.
117. [18260034] Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol. 2007 Sep;11(3):240-5.
118. [17515370] Fayad LM, Barker PB, Jacobs MA, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol. 2007 Jun;188(6):1513-20.
119. [16315208] Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging. 2006 Jan;23(1):23-8.
120. [10972550] Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med. 2000;18(3):193-8.
121. [8694528] Schick F, Duda SH, Lutz O, Claussen CD. Lipids in bone tumors assessed by magnetic resonance: chemical shift imaging and proton spectroscopy in vivo. Anticancer Res. 1996;16(3B):1569-74.
122. [15286325] Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, Tsai KB. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 232(2):599-605, 2004 Aug.
123. [18212197] Sah PL, Sharma R, Kandpal H, et al. In vivo proton spectroscopy of giant cell tumor of the bone. AJR Am J Roentgenol. 2008 Feb;190(2):W133-9.
124. [18356461] Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008 Apr;190(4):1097-104.
125. [18941746] Dinter DJ, Neff WK, Klaus J, et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol. 88(5):457-64, 2009 May.
126. [16896695] Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006 Oct;36(10):1019-31.
127. [19278802] Krohmer S, Sorge I, Krausse A, et al. Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol. 2010 Apr;74(1):256-61.
128. [19304704] Shortt CP, Gleeson TG, Breen KA, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009 Apr;192(4):980-6.
129. [30806604] Messiou C, Hillengass J, Delorme S, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019 Apr;291(1):5-13.
130. [7761640] Ma LD, Frassica FJ, Scott WW, Fishman EK, Zerbouni EA. Differentiation of benign and malignant musculoskeletal tumors: potential pitfalls with MR imaging. Radiographics. 1995 Mar;15(2):349-66.
131. [11392291] Peh WC, Chan JH. Artifacts in musculoskeletal magnetic resonance imaging: identification and correction. Skeletal Radiol. 2001 Apr;30(4):179-91.
132. [-3197621] American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2
133. [17515363] Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR. 2007; 188(6):1447-1474.
134. [-3197839] Shellock FG. Reference Manual for Magnetic Resonance Safety, Implants, and Devices. Playa Del Rey, CA Biomedical Research Publishing Group; 2013.
135. [15284433] Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004 Sep;232(3):635-52.
136. [-3197639] American College of Radiology. ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance (MR) Imaging Equipment. Available at https://gravitas.acr.org/PPTS/GetDocumentView?docId=57+&releaseId=2
137. [-3197846] Shellock FG. Magnetic Resonance Procedures: Health Effects and Safety. Boca Raton, Fla.: CRC Press; 2001.
138. [10931569] Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. J Magn Reson Imaging. 2000 Jul;12(1):92-106.